All In Biotech

Drug Trial Radar · NCT06200207

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

Effects of Ziltivekimab Versus Placebo on Heart Failure Symptoms and Physical Function in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 673 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

673

Planned (sponsor's estimate)

Start

Apr 1, 2024

Primary completion

Oct 1, 2026

Study completion Jan 8, 2027

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Jan 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.

Conditions

  • Heart Failure
  • Systemic Inflammation

Interventions

  • ZiltivekimabDrug

    Zilitivekimab will be administered subcutaneously once-monthly.

  • PlaceboDrug

    Placebo matched to ziltivekimab will be administered subcutaneously once-monthly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score (KCCQ-CSS)Time frame: From randomisation (month 0) to end-of-treatment (month 12)

Locations

217 sites in 16 countries. Site status is shown where the registry gives one.

  • Advanced Cardiovascular, LLC

    Alexander City, Alabama

  • Eastern Shore Rsrch Inst, LLC

    Fairhope, Alabama

  • Cardiology & Medicine Clinic

    Little Rock, Arkansas

  • Valley Clinical Trials, Inc.

    Northridge, California

  • UCI Health

    Orange, California

  • South California Heart Spc

    Pasadena, California

  • Clearwater Cardiovascular Consultants

    Largo, Florida

  • Ocala Cardiovascular Research

    Ocala, Florida

  • Ormond Beach Clinical Research

    Ormond Beach, Florida

  • St Johns Ctr Clin Rsch-St. Aug

    Saint Augustine, Florida

  • GA Arrhythmia Cons & Rsch Inst

    Macon, Georgia

  • Velocity Clin Rsrch - Savannah

    Savannah, Georgia

  • Chicago Medical Research LLC

    Hazel Crest, Illinois

  • UofL Health Care Outpatient

    Louisville, Kentucky

  • Maryland Cardiovascular Specialists - Baltimore

    Baltimore, Maryland

  • MD Medical Research

    Oxon Hill, Maryland

  • Cardio and Vascular Assoc-CAVA

    Bloomfield Hills, Michigan

  • Millennium Cardiology

    Farmington Hills, Michigan

  • Kansas City VA Medical Center

    Kansas City, Missouri

  • Washington University

    St Louis, Missouri

  • Renown Regional Medical Center

    Reno, Nevada

  • Long Island Cardiovascular Consultants PC

    Lake Success, New York

  • Mount Sinai Hosp at NYC

    New York, New York

  • Northwell Health Phys Cardio

    Riverhead, New York

  • University Of North Carolina At Chapel Hill

    Chapel Hill, North Carolina

  • AMS Cardiology

    Horsham, Pennsylvania

  • Univ of Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • PharmaTex Research

    Amarillo, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • David Turbay, MD, PLLC

    El Paso, Texas

  • Private Practice Leadership LLC.

    Katy, Texas

  • Clinical Advancement Center

    San Antonio, Texas

  • Clinical Advancement Ctr, PLLC

    San Antonio, Texas

  • Sherman Clinical Research

    Sherman, Texas

  • Northwest Heart Center

    Tomball, Texas

  • Sentara Health Research Center

    Norfolk, Virginia

  • Virginia Commonwealth University

    Richmond, Virginia

  • Instituto de Investigaciones Clinicas Quilmes SRL

    Buenos Aires, Argentina

  • CIPREC Pueyrredon

    Buenos Aires, Argentina

  • Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli

    Buenos Aires, Argentina

Showing 40 of 217 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.